Liver Imaging Reporting and Data System: current status and future perspectives in the diagnosis of hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and ranks third among cancer-related deaths globally, with over 900,000 new cases and approximately 830,000 deaths annually. Early detection is crucial, as 5-year survival exceeds 70% for lesions <3 cm treated curatively but drops below 20% in advanced stages. The Liver Imaging Reporting and Data System (LI-RADS) v2018, endorsed by major guidelines, provides a standardized framework for acquisition, interpretation, and reporting of liver lesions in high-risk patients. Using five major imaging features—non-rim arterial phase hyperenhancement, non-peripheral washout, enhancing capsule, lesion size, and threshold growth—alongside optional ancillary features, the LR-5 category achieves >95% positive predictive value for HCC. Meta-analyses of over 3300 observations report 86% sensitivity and 85% specificity for computed tomography/magnetic resonance imaging (MRI) LI-RADS, with gadoxetate-enhanced MRI reaching 88-91% sensitivity. Key limitations include overcalling benign hypervascular nodules, underdiagnosing hypovascular or well-differentiated HCC (up to 30% of lesions <2 cm), and misclassifying intrahepatic cholangiocarcinoma (CCA) or combined HCC-CCA as LR-5 (up to 40-50%). The LI-RADS Treatment Response Algorithm v2024 introduces criteria for radioembolization and stereotactic body radiation therapy, improving specificity for viable residual disease detection (93% vs. 86% for mRECIST). Future directions include artificial intelligence (82-90% accuracy), radiomics, multimodal imaging, and liquid biomarkers to reduce inter-reader variability and enhance prognostic stratification. Over a decade since its introduction, LI-RADS v2018 remains the reference standard for non-invasive HCC diagnosis and is evolving toward precision oncology.
References
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. DOI: https://doi.org/10.3322/caac.21660
- Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. DOI: https://doi.org/10.1038/s41572-020-00240-3
- Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76:681-93. DOI: https://doi.org/10.1016/j.jhep.2021.11.018
- Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology 2018;68:723-50. DOI: https://doi.org/10.1002/hep.29913
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. DOI: https://doi.org/10.1016/j.jhep.2018.03.019
- Kamal O, Roudenko A, Diab M, et al. Common pitfalls and diagnostic challenges in the application of LI-RADS CT/MRI algorithms: a comprehensive review. Abdom Radiol 2025;50:2944-57. DOI: https://doi.org/10.1007/s00261-024-04778-8
- Elsayes KM, Kielar AZ, Chernyak V, et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma 2019;6:49-69. DOI: https://doi.org/10.2147/JHC.S186239
- Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018;289:816-30. DOI: https://doi.org/10.1148/radiol.2018181494
- Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78:1922-65. DOI: https://doi.org/10.1097/HEP.0000000000000466
- Purysko AS, Remer EM, Coppa CP, et al. LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease. Radiographics 2012;32:1977-95. DOI: https://doi.org/10.1148/rg.327125026
- Tang A, Bashir MR, Corwin MT, et al. Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 2018;286:29-48. DOI: https://doi.org/10.1148/radiol.2017170554
- Ren AH, Zhao PF, Yang DW, et al. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. J Magn Reson Imaging 2019;50:746-55. DOI: https://doi.org/10.1002/jmri.26640
- Wakate Teruya AK, Miranda J, Leão Filho H, et al. LI-RADS TRA V2024: innovations in imaging assessment of hepatocellular carcinoma response to locoregional therapies. Abdom Radiol 2025. doi:10.1007/s00261-025-05110-8. DOI: https://doi.org/10.1007/s00261-025-05110-8
- Choi SY, Kim SH, Park CK, et al. Imaging features of gadoxetic acid-enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma. Radiology 2018;286:897-908. DOI: https://doi.org/10.1148/radiol.2017162846
- Liang Y, Xu F, Guo Y, et al. Diagnostic performance of LI-RADS for MRI and CT detection of HCC: a systematic review and diagnostic meta-analysis. Eur J Radiol 2021;134:109404. DOI: https://doi.org/10.1016/j.ejrad.2020.109404
- Shin J, Lee S, Yoon JK, et al. LI-RADS major features on MRI for diagnosing hepatocellular carcinoma: a systematic review and meta-analysis. J Magn Reson Imaging 2021;54:518-25. DOI: https://doi.org/10.1002/jmri.27570
- Chen J, Kuang S, Zhang Y, et al. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI. Abdom Radiol 2021;46:1530-1542. DOI: https://doi.org/10.1007/s00261-020-02790-2
- Liu Q, Liu T, Liu X, et al. The efficacy of modified contrast-enhanced ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) using Sonazoid in diagnosis of hepatocellular carcinoma. Quant Imaging Med Surg 2024;14:2927-37. DOI: https://doi.org/10.21037/qims-23-1184
- Cao J, Shon A, Yoon L, et al. Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease. Eur Radiol 2024;34:7622-31. DOI: https://doi.org/10.1007/s00330-024-10846-w
- Kim DH, Kim B, Choi JI, et al. LI-RADS treatment response versus modified RECIST for diagnosing viable hepatocellular carcinoma after locoregional therapy. Taehan Yongsang Uihakhoe Chi 2022;83:331-43. DOI: https://doi.org/10.3348/jksr.2021.0173
- Jang HJ, Choi SH, Choi SJ, et al. LI-RADS version 2018 for hepatocellular carcinoma <1.0 cm on gadoxetate disodium-enhanced magnetic resonance imaging. Eur Radiol 2023;33:5792-800. DOI: https://doi.org/10.1007/s00330-023-09554-8
- Eschrich J, Kobus Z, Geisel D, et al. The diagnostic approach towards combined hepatocellular-cholangiocarcinoma – state of the art and future perspectives. Cancers 2023;15:301. DOI: https://doi.org/10.3390/cancers15010301
- Barat M, Nguyen TTL, Hollande C, et al. LI-RADS v2018 major criteria: do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI? Eur J Radiol 2021;138:109651. DOI: https://doi.org/10.1016/j.ejrad.2021.109651
- Mulé S, Ronot M, Ghosn M, et al. Automated CT LI-RADS v2018 scoring of liver observations using machine learning. JHEP Rep 2023;5:100857 DOI: https://doi.org/10.1016/j.jhepr.2023.100857
- Zhang J, Liu J, Guo M, et al. DeepSeek-assisted LI-RADS classification: AI-driven precision in hepatocellular carcinoma diagnosis. Int J Surg 2025;111:5970-9. DOI: https://doi.org/10.1097/JS9.0000000000002763
- Park J, Bae JS, Kim JM, et al. Development of a deep-learning model for classification of LI-RADS major features by using subtraction images of MRI. Abdom Radiol 2023;48:2547-56. DOI: https://doi.org/10.1007/s00261-023-03962-6
- Xiao M, Deng Y, Zheng W, et al. Machine learning model based on dynamic contrast-enhanced ultrasound assisting LI-RADS diagnosis of HCC. Heliyon 2024;10:e38850. DOI: https://doi.org/10.1016/j.heliyon.2024.e38850
- Liang L, Pang J, Zhang B, et al. Integrating CEUS imaging features and LI-RADS classification for postoperative early recurrence prediction in solitary hepatocellular carcinoma. J Hepatocell Carcinoma 2025;12:1287-300. DOI: https://doi.org/10.2147/JHC.S530848
- Huang H, Cheng MQ, He DN, et al. US LI-RADS in surveillance for recurrent hepatocellular carcinoma after curative treatment. Eur Radiol. 2023;33:9357-67. DOI: https://doi.org/10.1007/s00330-023-09903-7
- Wei H, Yang T, Chen J, et al. Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions. Liver Int 2022;42:2131-44. DOI: https://doi.org/10.1111/liv.15362
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2026 the Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.